Search results for "Poster Abstracts"
showing 2 items of 2 documents
AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer
2019
BACKGROUND: Transforming growth factor β (TGF-β) signaling promotes tumor immunosuppression; its inhibition in the tumor microenvironment may enhance the response to anti-PD-L1 treatment. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 mAb against PD-L1. Building upon encouraging efficacy observed in a phase 1 study, the present study will evaluate M7824 clinical benefit in patients with pretreated biliary tract cancer (BTC). METHODS: This multicenter, international trial is evaluating M7824 monotherapy in patients with locally advanced or metastatic (LA/M) BTC unselected for tumor PD-L1…
iPRG 2012 Study: Detecting Modified Peptides in a Complex Mixture
2012
Nature uses a wide variety of protein post-translational modifications to regulate protein structure and activity and tandem mass spectrometry has emerged as the most powerful analytical approach to detect these moieties. However, modified peptides present special challenges for characterization. First, they are generally present at sub-stoichiometric levels, meaning that without enrichment strategies samples are dominated by unmodified peptides, so finding the modified peptides may be a challenge. Secondly, the modifications may have unique fragmentation behaviors in collision-induced dissociation (CID), which may need to be considered by database search engines. Finally, if there are mult…